Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
Vaccinex (VCNX) has announced its decision to voluntarily delist its common stock from the Nasdaq Stock Market. This follows a suspension of trading since December 18, 2024, and a notice dated December 16, 2024, from the Nasdaq Hearings Panel determining to delist the company's securities.
The biotechnology company plans to file a Form 25 with the SEC around March 17, 2025, to formally remove its listing. Despite the delisting, Vaccinex intends to continue developing its lead product, pepinemab, targeting Alzheimer's disease and cancer treatments through partnerships, grants, and alternative financing methods.
Vaccinex (VCNX) ha annunciato la sua decisione di ritirare volontariamente le sue azioni ordinarie dal mercato azionario Nasdaq. Questa decisione segue una sospensione delle contrattazioni dal 18 dicembre 2024 e una comunicazione datata 16 dicembre 2024, da parte del Nasdaq Hearings Panel, che ha determinato di delistare i titoli dell'azienda.
La società biotecnologica prevede di presentare un modulo 25 alla SEC intorno al 17 marzo 2025, per rimuovere formalmente la sua quotazione. Nonostante il delisting, Vaccinex intende continuare a sviluppare il suo prodotto di punta, pepinemab, mirato al trattamento dell'Alzheimer e del cancro attraverso partnership, sovvenzioni e metodi di finanziamento alternativi.
Vaccinex (VCNX) ha anunciado su decisión de eliminar voluntariamente sus acciones ordinarias del mercado de valores Nasdaq. Esta decisión sigue a una suspensión de la negociación desde el 18 de diciembre de 2024 y un aviso fechado el 16 de diciembre de 2024, del Panel de Audiencias de Nasdaq, que determinó eliminar los valores de la empresa.
La empresa biotecnológica planea presentar un Formulario 25 ante la SEC alrededor del 17 de marzo de 2025, para eliminar formalmente su cotización. A pesar del deslistado, Vaccinex tiene la intención de continuar desarrollando su producto principal, pepinemab, dirigido a tratamientos para el Alzheimer y el cáncer a través de asociaciones, subvenciones y métodos de financiamiento alternativos.
Vaccinex (VCNX)는 자사의 보통주를 나스닥 증권거래소에서 자발적으로 상장 폐지하기로 결정했다고 발표했습니다. 이는 2024년 12월 18일부터 거래가 중단된 이후의 결정이며, 2024년 12월 16일자 나스닥 청문위원회의 통지에 따라 회사의 증권을 상장 폐지하기로 했습니다.
이 생명공학 회사는 2025년 3월 17일경에 SEC에 양식 25를 제출하여 상장을 공식적으로 제거할 계획입니다. 상장 폐지에도 불구하고 Vaccinex는 알츠하이머병 및 암 치료를 위한 파트너십, 보조금 및 대체 자금 조달 방법을 통해 주요 제품인 pepinemab의 개발을 계속할 계획입니다.
Vaccinex (VCNX) a annoncé sa décision de retirer volontairement ses actions ordinaires du marché boursier Nasdaq. Cette décision fait suite à une suspension de la négociation depuis le 18 décembre 2024 et à un avis daté du 16 décembre 2024, du Panel d'Auditions Nasdaq, qui a décidé de radier les titres de la société.
La société biotechnologique prévoit de déposer un formulaire 25 auprès de la SEC aux alentours du 17 mars 2025, pour retirer officiellement sa cotation. Malgré le retrait, Vaccinex a l'intention de continuer à développer son produit phare, pepinemab, ciblant les traitements de la maladie d'Alzheimer et du cancer par le biais de partenariats, de subventions et de méthodes de financement alternatives.
Vaccinex (VCNX) hat seine Entscheidung bekannt gegeben, seine Stammaktien freiwillig vom Nasdaq Aktienmarkt abzuziehen. Dies folgt auf eine Handelsaussetzung seit dem 18. Dezember 2024 und eine Mitteilung vom 16. Dezember 2024, in der das Nasdaq Hearings Panel beschlossen hat, die Wertpapiere des Unternehmens abzulehnen.
Das Biotechnologieunternehmen plant, um den 17. März 2025 ein Formular 25 bei der SEC einzureichen, um seine Notierung offiziell zu entfernen. Trotz der Abmeldung beabsichtigt Vaccinex, die Entwicklung seines Hauptprodukts, pepinemab, das auf die Behandlung von Alzheimer und Krebs abzielt, durch Partnerschaften, Zuschüsse und alternative Finanzierungswege fortzusetzen.
- Continuing development of lead product pepinemab
- Pursuing alternative funding through partnerships and grants
- Forced delisting from Nasdaq Stock Market
- Trading suspension since December 18, 2024
- Loss of major exchange listing status could impact investor access and liquidity
- Company needs to seek alternative financing methods
ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market (“Nasdaq”) of its decision to delist the Company’s shares of common stock, par value
Vaccinex intends to file a Form 25 with the Securities and Exchange Commission on or about March 17, 2025 to remove its Common Stock from listing on Nasdaq.
The Company’s decision to delist follows its receipt of notice dated December 16, 2024, that the Nasdaq Hearings Panel had determined to delist the Company’s securities from Nasdaq, and the subsequent suspension of trading. Nasdaq would have otherwise filed a Form 25 in due course.
The Company plans to continue to focus on development of its lead product, pepinemab, to treat Alzheimer’s disease and cancer through partnerships, grants and other financing avenues.
About Vaccinex Inc.
Vaccinex, Inc. is pioneering a differentiated approach to treating slowly progressive neurodegenerative diseases and cancer through the inhibition of semaphorin 4D (SEMA4D). The Company’s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes triggers damaging inflammation in chronic diseases of the brain and prevents infiltration and activation of immune cells in tumors. Pepinemab was studied as a monotherapy in the Phase 1b/2 SIGNAL-AD study in Alzheimer’s Disease, and the Company has previously published promising Phase 2 data in Huntington’s disease. Vaccinex believes pepinemab could also be an important contributor to combination therapy in AD. In oncology, pepinemab is being evaluated in combination with KEYTRUDA® in the Phase 1b/2 KEYNOTE-B84 study in recurrent or metastatic head and neck cancer (HNSCC) and in combination with BAVENCIO® in a Phase 1b/2 study in patients with metastatic pancreatic adenocarcinoma (PDAC). The oncology clinical program also includes several investigator-sponsored studies in solid tumors including breast cancer and melanoma.
Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of Merck and Co, Inc. Kenilworth, NJ, USA.
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA. BAVENCIO®/avelumab is provided by Merck KGaA, Darmstadt, Germany, previously as part of an alliance between the healthcare business of Merck KGaA, Darmstadt, Germany and Pfizer.
About Pepinemab
Pepinemab is a humanized IgG4 monoclonal antibody designed to block SEMA4D, which can bind to plexin-B1 receptors to trigger collapse of the actin cytoskeleton in cells and lead to loss of homeostatic functions of astrocytes and other glial cells in the brain and of dendritic cells in immune tissue. Pepinemab appears to have been well-tolerated with a favorable safety profile in multiple clinical trials in different neurological and cancer indications.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Vaccinex, Inc. (“Vaccinex,” “we,” “us,” or “our”), they may be forward-looking statements reflecting management’s current beliefs and expectations. Such statements include, but are not limited to, statements identified by words such as “may,” “will,” “intends,” “plans,” “expects,” and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances). These statements include, among others, those regarding the expected timing of the delisting from Nasdaq and expected benefits of delisting. These statements are based on our current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in our periodic reports filed with the Securities and Exchange Commission and the other risks and uncertainties described in Vaccinex’s most recent year-end Annual Report on Form 10-K and subsequent SEC filings.
Investor Contact
Elizabeth Evans, PhD
Chief Operating Officer, Vaccinex, Inc.
(585) 766-2033
eevans@vaccinex.com
FAQ
When will Vaccinex (VCNX) be officially delisted from Nasdaq?
Why is Vaccinex (VCNX) being delisted from Nasdaq?
What happens to Vaccinex's (VCNX) drug development programs after delisting?
When was VCNX stock trading suspended on Nasdaq?
